Johnson & Johnson stock price nudges higher after BofA target hike; investors eye April 14 update

March 3, 2026
Johnson & Johnson stock price nudges higher after BofA target hike; investors eye April 14 update

New York, March 2, 2026, 19:03 EST — After-hours

  • JNJ picked up 0.05% to finish at $248.56. The stock moved between $246.87 and $251.71 during the session.
  • Tim Anderson at BofA bumped up his Johnson & Johnson price target, moving it to $253 from $227.
  • Johnson & Johnson plans to go over its first-quarter results on a conference call scheduled for April 14.

Johnson & Johnson ticked 0.05% higher to $248.56 in Monday’s after-hours session, following a price target bump from a Bank of America analyst and news of an April 14 call for its first-quarter update. Shares swung from $246.87 to $251.71 during regular trading. 1

Timing’s key here: investors are already penciling in dates and building bets ahead of the next earnings cycle, with J&J’s shares hovering close to recent peaks. BofA stuck to its Neutral call — basically a “hold” — despite bumping up its price target, citing little room to run at this valuation and ongoing litigation overhang. 2

Johnson & Johnson has set a conference call for 8:30 a.m. Eastern on Tuesday, April 14. CEO Joaquin Duato and CFO Joseph J. Wolk are among the executives scheduled to speak. That’s when investors will get the next firm update on guidance and sales trends in both the drug and medical-device segments. 3

Shares kicked off at $249.19, swung through a broad range, then closed out near $248.56. Trading volume hit about 8.7 million shares, market data showed. 4

Anderson is now looking for $253, roughly 2% higher than where shares closed on Monday. That’s just his forecast for where the stock might land in the next year—no guarantees.

But there’s a significant hitch. Johnson & Johnson is still tangled in the larger talc lawsuit battle, where courtroom shifts have the power to shake investor mood—even if the fundamentals hold up. 5

Investors outside the courtroom are quick to home in on whether fresh drugs can sustain momentum as legacy products age and pricing dynamics evolve. Those are typically their opening questions.

Tuesday, traders eye whether the stock stays pinned near the top of its recent band after Monday’s sharp move. Attention also turns to any aftershocks from the late analyst call.

Johnson & Johnson expects to drop its quarterly results at about 6:45 a.m. ET on April 14, before its scheduled call and webcast. That’s the next key date for JNJ’s share price movement. 6